Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 11/20 | 0.34 |
| ▸ | P2RX1 | P51575 | 5/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7448875 | 0.98 | MAPK1 (0.38) | LMNAMAPK1TSHRSCN4ASCN5A | |
| SCHEMBL29434173 | 0.76 | P2RX4 (0.37) | LMNAMAPK1TSHRSCN4ASCN5A | |
| SCHEMBL1198914 | 0.76 | P2RX4 (0.37) | LMNAMAPK1TSHRSCN4ASCN5A | |
| SCHEMBL4540872 | 0.74 | MAPK1 (0.35) | LMNAMAPK1TSHRSCN4ASCN5A | |
| SCHEMBL2073989 | 0.74 | MAPK1 (0.35) | LMNAMAPK1TSHRSCN4ASCN5A | |
| Iodide SCHEMBL7101346 | 0.74 | P2RX4 (0.36) | LMNAMAPK1TSHRSCN4ASCN5A | |
| SCHEMBL374978 | 0.74 | MAPK1 (0.39) | LMNAMAPK1TSHRSCN4ASCN5A | |
| SCHEMBL5213962 | 0.74 | MAPK1 (0.35) | LMNAMAPK1TSHRSCN4ASCN5A | |
| SCHEMBL8857358 | 0.74 | MAPK1 (0.35) | LMNAMAPK1TSHRSCN4ASCN5A | |
| SCHEMBL29506717 | 0.74 | MAPK1 (0.39) | LMNAMAPK1TSHRSCN4ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2950649-A2 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY | Wellstat Therapeutics Corporation (US) | 2015-12-09 | — | — | EP | claimed |
| WO-2014120995-A2 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY | WELLSTAT THERAPEUTICS CORPORATION (US) | 2014-08-07 | — | — | WO | claimed |
| CN-102216298-B | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR INC | 2014-04-16 | — | — | CN | claimed |
| CN-101061118-A | Substituted bicyclic imidazo-3-ylamine compounds | GRUENENTHAL GMBH (DE) | 2007-10-24 | — | — | CN | claimed |
| WO-1999067238-A2 | TETRAHYDROQUINOLINE-INDOLE DERIVATIVES ANTIMICROBIAL AGENTS, THEIR USES AND COMPOSITIONS CONTAINING THEM | SEPRACOR, INC. (US) | 1999-12-29 | — | — | WO | claimed |
| US-20250223261-A1 | PROCESS FOR MAKING A TASTE-MODIFYING COMPOUND | FIRMENICH SA (CH) | 2025-07-10 | — | — | US | disclosed |
| US-20240101531-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | XENON PHARMACEUTICALS INC. (CA) | 2024-03-28 | — | — | US | disclosed |
| US-20230390259-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-12-07 | — | — | US | disclosed |
| WO-2023209143-A1 | PROCESS FOR MAKING A TASTE-MODIFYING COMPOUND | FIRMENICH SA (CH) | 2023-11-02 | — | — | WO | disclosed |
| CN-114751903-B | Nitrogen-containing fused heterocycle SHP2 inhibitor compound, preparation method and application | 上海凌达生物医药有限公司 | 2023-09-15 | — | — | CN | disclosed |
| US-20210085658-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO., LTD. | 2021-03-25 | — | — | US | disclosed |
| US-10456385-B2 | Pharmaceutical composition comprising pyridone derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2019-10-29 | — | — | US | disclosed |
| CN-1784231-A | 1-amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES CO (US) | 2006-06-07 | — | — | CN | disclosed |
| WO-2003013523-A1 | SH3 PROTEIN DOMAINS AND THEIR LIGANDS | ADELAIDE RESEARCH & INNOVATION PTY LTD (AU) | 2003-02-20 | — | — | WO | disclosed |
| EP-0470578-B1 | Novel tricyclic compound or salts thereof, method for producing the same and antimicrobial agent containing the same | WAKUNAGA SEIYAKU KK (JP) | 1996-11-06 | — | — | EP | disclosed |
| US-5399553-A | Oral absorbability | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1995-03-21 | — | — | US | disclosed |
| US-5254685-A | Tricyclic compound or salts thereof, method for producing the same and antimicrobial agent containing the same | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1993-10-19 | — | — | US | disclosed |
| CN-1059144-A | New tricyclic compound or its salt, prepare their method and contain their antiseptic-germicide | WAKUNAGA SEIYAKU KK (JP) | 1992-03-04 | — | — | CN | disclosed |
| EP-0470578-A1 | Novel tricyclic compound or salts thereof, method for producing the same and antimicrobial agent containing the same | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1992-02-12 | — | — | EP | disclosed |
| WO-1990005523-A2 | PHENANTHROLINEDICARBOXYLATE ESTERS, 4-AMINOQUINOLINE AND ISOQUINOLINE DERIVATIVES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | THE UPJOHN COMPANY (US) | 1990-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223261-A1 | PROCESS FOR MAKING A TASTE-MODIFYING COMPOUND | TAS2R4, TAS2R50, TAS2R60 | LMNA 4091/4885MAPK1 1603/4885TSHR 4372/4885 |
| US-20240101531-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNA1, KCNB1, KCNB2 | LMNA 739/4885MAPK1 720/4885TSHR 1321/4885 |
| US-20230390259-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | PLPBP, PDXK, PIR | LMNA 2543/4885MAPK1 1773/4885TSHR 3361/4885 |
| US-10456385-B2 | Pharmaceutical composition comprising pyridone derivatives | PLPBP, PDXK, PIR | LMNA 2543/4885MAPK1 1773/4885TSHR 3361/4885 |
| US-20210085658-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDONE DERIVATIVES | PLPBP, PDXK, PNPO | LMNA 2494/4885MAPK1 1666/4885TSHR 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.